Moreover, a recent study demonstrated that EGFR tyrosine kinase inhibitors such as gefitinib and erlotinib, already used clinically as chemotherapy for non-small cell lung cancer, inhibited RIP2 tyrosine phosphorylation and MDP-induced cytokine release, but not in an EGFR-dependent manner [45]. Here, RIPK2 is linked to non-small cell lung carcinoma.